KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Non-Current Deffered Revenue (2019 - 2025)

Historic Non-Current Deffered Revenue for West Pharmaceutical Services (WST) over the last 10 years, with Q4 2025 value amounting to $13.5 million.

  • West Pharmaceutical Services' Non-Current Deffered Revenue fell 1233.77% to $13.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $13.5 million, marking a year-over-year decrease of 1233.77%. This contributed to the annual value of $13.5 million for FY2025, which is 1233.77% down from last year.
  • As of Q4 2025, West Pharmaceutical Services' Non-Current Deffered Revenue stood at $13.5 million, which was down 1233.77% from $13.5 million recorded in Q3 2025.
  • In the past 5 years, West Pharmaceutical Services' Non-Current Deffered Revenue registered a high of $28.9 million during Q4 2021, and its lowest value of $11.4 million during Q1 2025.
  • In the last 5 years, West Pharmaceutical Services' Non-Current Deffered Revenue had a median value of $18.8 million in 2023 and averaged $19.0 million.
  • Per our database at Business Quant, West Pharmaceutical Services' Non-Current Deffered Revenue skyrocketed by 2620.09% in 2021 and then plummeted by 3870.97% in 2025.
  • Over the past 5 years, West Pharmaceutical Services' Non-Current Deffered Revenue (Quarter) stood at $28.9 million in 2021, then plummeted by 33.91% to $19.1 million in 2022, then fell by 2.62% to $18.6 million in 2023, then dropped by 17.2% to $15.4 million in 2024, then fell by 12.34% to $13.5 million in 2025.
  • Its last three reported values are $13.5 million in Q4 2025, $13.5 million for Q3 2025, and $12.5 million during Q2 2025.